Artificial Intelligence Meets Bioequivalence: Using Generative Adversarial Networks for Smarter, Smaller Trials

This study introduces artificial intelligence as a powerful tool to transform bioequivalence (BE) trials. We apply advanced generative models, specifically Wasserstein Generative Adversarial Networks (WGANs), to create virtual subjects and reduce the need for real human participants in generic drug...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasios Nikolopoulos, Vangelis D. Karalis
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Machine Learning and Knowledge Extraction
Subjects:
Online Access:https://www.mdpi.com/2504-4990/7/2/47
Tags: Add Tag
No Tags, Be the first to tag this record!